Abstract: Formulations and methods for growing hone in a site specific location using an osteogenic molecule such as a prostaglandin, and a delivery vehicle which is preferably a polymer matrix.

Abstract: Described are a sterile, ready-to-use, pharmaceutical oil-in water emulsion compositions for parenteral administration comprising: 0.015 to 1.2% wt/vol of progestogen; 0.5-30% wt/vol oil, wherein the oil comprises at least 85% wt/wt triglyceride; 0.0425-12.5% wt/vol phospholipid; 61.4-99.4% wt/vol aqueous medium; wherein the phospholipid is present in an amount of 6.8%-43% of the oil (wt/wt), and wherein the progestogen is present in an amount greater than or equal to 2.1 wt % of the oil. Also described are methods of making such compositions and method of using such compositions in therapeutic or prophylactic treatment, such as treatments comprising intravenous administration of the pharmaceutical composition.

Abstract: The present invention describes processes for the preparation of a lipid blend and a uniform filterable phospholipid suspension containing the lipid blend, such suspension being useful as an ultrasound contrast agent.

Abstract: Embodiments may include a method for reducing a solvent concentration in a plurality of microparticles. The method may involve contacting a mixture including the plurality of microparticles and the solvent with water to form an aqueous suspension. A first portion of the solvent may dissolve into the water of the aqueous suspension to reduce the solvent concentration in the plurality of microparticles from a first solvent concentration in the mixture to a second solvent concentration in the aqueous suspension. The method may also include transferring the aqueous suspension to a concentration unit that may further reduce the solvent concentration from the second solvent concentration to a third solvent concentration. The method may further include transferring a microparticle concentrate with the third solvent concentration to a washing unit to form an amalgam of washed microparticles with a fourth solvent concentration. The method may also include drying the amalgam of washed microparticles.

Abstract: A reagent assay in accordance with the present disclosure has a porous alginate core containing a first reagent, a first polysaccharide layer coating the alginate core and having a second reagent, and at least one polysaccharide core comprising a hydration seal and coating the first polysaccharide layer.

Abstract: Provided herein, are droplet mixture compositions and systems and methods for forming mixtures of droplets. The system may comprise two or more droplet generation units. Each unit may include at least one first input well, a second input well, and an output well connected to the first and second input wells by channels that form a droplet generator. The combined droplet populations can be mixed, heated, and collected for multiple uses, such as for use as calibration standards for instrument testing and analysis.

Abstract: The present invention relates to conjugates comprising a peptide of at least 10 amino acid residues comprising the amino acid sequence GITELKKL (residues 383-390 of SEQ ID NO: 3) for induction of potent humoral and cellular immune responses when administered to subjects having antibodies against tetanus toxoid. In one embodiment the invention relates to a prophylactic and therapeutic vaccine and in a further embodiment the invention relates to the treatment or prevention of cancer or an infectious disease.

Abstract: The present invention relates to emulsion and double-emulsion based processes for preparing microparticles. The invention also relates to workhead assemblies for in-line flow-through mixing devices that can be used for mixing two or more fluids. The workhead assemblies can be used with the processes for preparing microparticles.

Abstract: In one embodiment, the present application discloses synthetic LDL nanoparticles comprising mixtures of components selected from the group consisting of phospholipids, triglycerides, cholesterol ester and free cholesterol; optionally further comprising an agent selected from the group consisting of natural antioxidants, ubiquinol and vitamin E, and methods for preparing the synthetic nanoparticles. The disclosed synthetic LDL nanoparticles are capable of selectively delivering lipophilic drugs and prodrugs to cellular targets expressing LDL receptors after intra venous injection.

Abstract: The need for a treatment composition which provides a pleasant odor to a treated situs, particularly one having a long-lasting woody, floral, fruity or citrus character, and which does not discolor over time, is met by formulating the treatment composition with microcapsules comprising a microcapsule wall formed from cross-linked formaldehyde, and a core comprising an aldehyde or ketone containing perfume, in combination with a formaldehyde scavenger which does not complex with the aldehyde and/or ketone and amine, to form complexes that result in discoloration.

Abstract: Specific peptides derived from the cytotoxicity receptor natural killer protein 44 (NKp44) useful for treating diseases such as cancer are described. The invention further relates to compositions comprising a fragment of the extracellular region of NKp44 for preventing or treating cancer.

Abstract: Nanolipidic Particles (NLPs) having average mean diameters of 1 nm to 20 nm are made from a precursor solution. NLPs can be loaded with a desired passenger molecule. Assemblies of these particles, called NLP assemblies, result in a vehicle population of a desired size. Single application or multifunction NLP assemblies are made from the loaded NLPs and range in size from about 30 nm to about 200 nm. A method of using preloaded NLPs to make larger carrier vehicles or a mixed population provides increased encapsulation efficiency. NLPs have application in the cosmetics, pharmaceutical, and food and beverage industries.

Abstract: Disclosed herein are sterile-filtered lyophilized nanoparticle compositions which contain at least one biodegradable polymer, at least one surfactant, at least one cryoprotective agent and at least one antigen. Also disclosed are methods of making and using such compositions and kits supplying such compositions.

Abstract: The present invention provides for methods of preparing silk nanoparticles and microparticles, methods of encapsulating an active agent into the silk nano- and microparticles and compositions comprising these silk particles. In particular, the silk spheres are prepared from phase separation of silk and polyvinyl alcohol (PVA), without exposure to an organic solvent. The method employs a chemical, PVA, which is an FDA-approved ingredient in drug formulations. Different parameters can be adjusted to control the size and shape of the silk spheres during the fabrication process. The silk particle compositions of the present invention may also encapsulate active agents or chemicals. Such compositions allow the active agents to be controllably and sustainably released to the target organs or tissues. The silk composition entrapping active agents also provides for a long-term storage medium for the active agents so entrapped.

Abstract: A continuous process for the preparation of gelatin based nanoparticles in a reactor having a process channel having a mixing element therein, the process having the following steps: A) feeding separately an aqueous gelatin solution at a first rate and a water-miscible organic solvent at a second rate to the process channel of the reactor to be mixed therein, to form a suspension of non-crosslinked gelatin based nanoparticles and B) crosslinking the non-crosslinked gelatin based nanoparticles, wherein the sum of the first rate and the second rate is chosen such that the reactor has a mixing efficiency as determined by the Villermaux/Dushman method of between 0.1 and 1.5 and the period from the time point at which the aqueous gelatin solution is fed to the reactor to the time point at which the mixture of the aqueous gelatin solution and the organic solvent contacts the mixing element is at most 15 seconds.

Abstract: Phase change material microcapsules are obtained using a PMMA prepolymer and an organic-solvent free synthesis process. A polymer monomer and an initiator are subject to pre-polymerization in a water bath to form Polymethyl methacrylate (PMMA) prepolymer which is then prepared to be a stabilizer aqueous solution. A phase change material is added to the stabilizer aqueous solution and liquefied in advance, and stirred to form an emulsion by a homogenizing mixer. A starting agent, a cross-linking agent and a Polymethyl methacrylate methyl ester prepolymer are added to the emulsion containing the phase-change material. The emulsion is further stirred by the homogenizing mixer for micro-emulsification which then aggregates in water bath.

Abstract: Disclosed herein are a nanopreparation having a micelle structure for diagnosis or treatment of cancer diseases, and a method of preparing the same, and more particularly, a nanopreparation having a micelle structure available for diagonosis or treatment of cancer diseases and a method for preparing the same, wherein the nanopreparation is prepared by encapsulating a photosensitizer by forming micelle with polymeric lipid DSPE-mPEG. The nanopreparation having the micelle structure according to the present invention has a size of 12 nm or less by encapsulating hypericin, which is a photosensitizer, by forming micelle with polymeric lipid DSPE-mPEG having a molecular weight of 1500 to 2500. Resultingly, the nanopreparation easily overcomes a blood-tumor barrier (BTB) and an interstitial fluid pressure and has light induced cytotoxicity efficiency that is about more than 2.5 times higher than that of the case where hypericin is used alone.

Abstract: An object of the present invention is to provide a method for producing composite particles of at least one of a curing agent and a curing accelerator which have excellent release properties for at least one of the curing agent and curing accelerator, exhibit excellent rapid curability when contained in a curable resin composition, and have excellent storage stability; and the composite particles of at least one of the curing agent and the curing accelerator. Another object of the present invention is to provide to a thermosetting resin composition that contains the composite particles of at least one of the curing agent and the curing accelerator. The method of the present invention includes the steps of: preparing an emulsion in which droplets containing a compound for forming shells are dispersed in an aqueous medium; impregnating the droplets with at least one of a curing agent and a curing accelerator; and forming shells each enclosing the at least one of the curing agent and the curing accelerator.

Abstract: A capsule having a solid core, a primary shell of liquid encapsulating the solid core and a secondary shell of particles encapsulating the primary shell. The primary and secondary shells are generally repulsive to each other. Also provided is a process for the manufacture of capsules and a process for the manufacture of a magnetic body.

Abstract: Microfluidic methods and systems are provided for continuous flow synthesis and active loading of liposomes, which include a liposome formation region configured to form a population of liposomes and a microdialysis region downstream from the liposome formation region and configured to form a transmembrane gradient for active drug loading of the liposomes. Microfluidic methods and systems for high throughput production of liposomes are also provided featuring high aspect ratio microchannels.

Abstract: Prior art processes for producing protein-based capsules (for example, capsules for use in electrophoretic media) tend to be wasteful because they produce many capsules outside the desired size range, which is typically about 20 to 50 ?m. Capsule size distribution and yields can be improved by either (a) emulsifying a water-immiscible phase in a preformed coacervate of the protein; or (b) using a limited coalescence process with colloidal alumina as the surface-active particulate material.

Abstract: The present invention provides a long circulating non-pegylated liposomal doxorubicin hydrochloride composition for parenteral administration and a process for its preparation. The circulation time in Swiss albino mice is at least 25 times longer than conventional non-liposomal formulations. The non-pegylated liposomes are stable, exhibit low toxicity and have been found to be efficacious in different tumor models.

Abstract: Chemoselective ligation of hydrophobic reactants in a lipid phase.

Abstract: This invention relates to a method for forming hollow silica-based particles suitable for containing one or more active ingredients or for containing other smaller particles which may include one or more active ingredients. In the method, an emulsion is prepared including a continuous phase that is polar or non-polar, and a dispersed phase comprising droplets including (i) a polar active ingredient when the continuous phase is non-polar or (ii) a non-polar active ingredient when the continuous phase is polar; and a prehydrolyzed silica precursor is added to the emulsion such that the silica precursor can be emulsion templated on the droplets to form hollow silica-based particles.

Abstract: Compositions and methods are described for preparing media, feeds, and supplements. Such methods and medias may display increased stability of labile components and may use, for example, microsuspension and/or encapsulation technologies, chelation, and optionally, coating and/or mixing the labile compounds with anti-oxidants. The compositions may withstand thermal and/or irradiation treatment and have reduced virus number. These techniques may result in product with extended shelf-life, extended release of their internal components into culture, or in product that can be added aseptically into a bioreactor using minimal volumes. The compositions and methods may optimize the bioproduction workflow and increase efficiency.

Abstract: A method of making capsules includes forming a mixture including a core liquid, a polyurethane precursor system, a first component of a two-component poly(urea-formaldehyde) precursor system, and a solvent. The method further includes emulsifying the mixture, adding a second component of the two-component poly(urea-formaldehyde) precursor system to the emulsified mixture, and maintaining the emulsified mixture at a temperature and for a time sufficient to form a plurality of capsules that encapsulate at least a portion of the core liquid. The capsules made by the method may include a polymerizer in the capsules, where the capsules have an inner capsule wall including a polyurethane, and an outer capsule wall including a poly(urea-formaldehyde). The capsules may include in the solid polymer matrix of a composite material.

Abstract: Disclosed are: an apparatus which enables the easy production of liposomes having uniform particle diameters; and others. Specifically disclosed is a liposome production apparatus comprising: a microtube having a flow path through which a lipid-dissolved solution comprising at least one lipid, water and a water-miscible organic solvent can pass; a housing section in which the microtube is accommodated; and a cooling means for cooling the dissolved solution contained in the microtube in the housing section to a temperature at which liposomes can be produced. The apparatus enables the production of liposomes having uniform particle diameters.

Abstract: Disclosed is a device for preparation of liposomes, comprises a reaction tank and an infusion unit. The reaction tank comprises a collector mounted in a predetermined position of the reaction tank; Two inlet ports are included: the first inlet port for infusing an aqueous solution; and the second inlet port for infusing an organic solution. The infusion unit can introduce a bioactive agent containing-aqueous solution into the reaction tank. The infusion unit comprises a filter connected to one end of the infusion unit and being adjacent to the collector.

Abstract: A production method is provided for obtaining a biologically ingestible material having an intended diameter with low energy as compared with conventional methods. The method includes mixing a fluid to be processed in a dispersed phase containing a pharmacologically active substance and a fluid to be processed in a continuous phase including at least a disperse solvent, while each of the fluids is retained in an independent state, in a thin film fluid formed between two processing surfaces arranged to be opposite to each other to be able to approach to and separate from each other, at least one of which rotates relative to the other, through independent pathways corresponding to the respective phases, whereby the components contained in the fluid to be processed in a dispersed phase are formed into microparticles having a desired diameter.

Abstract: Provided herein is a process for preparing a microparticulate complex of a particle-forming component (“PFC”) and a nucleic acid-like component (“NAC”) in a monophasic composition comprising water and a water-miscible organic solvent. Also provided is a microparticulate complex that comprises a particle-forming component complexed to a nucleic acid-like component, and a composition comprising water and the microparticulate complex. Further provided is a method of delivery of a nucleic acid-like component to a cell or to a patient by contacting the cell with or administering to the patient a composition comprising water and the microparticulate complex described herein. Still further, a charge-changing composition represented by the formula A-X—B is provided.

Abstract: Various lipid nanoparticles are disclosed, including nanoparticles comprising a lipid bilayer comprising a phospholipid, a sterol, a polyethylene glycol-lipid surrounding an aqueous core which comprises a therapeutic and/or diagnostic agent and nanoparticles comprising a lipid monolayer surrounding a hydrophobic core. Of particular interest are limit size lipid nanoparticles with a diameter from 10-100 nm. Such lipid nanoparticles are the smallest particles possible for a specific particle composition. Methods and apparatus for preparing such limit size lipid nanoparticles are disclosed.

Abstract: Methods to produce pH-sensitive microparticles that have an active agent dispersed in a polymer matrix have certain advantages over microcapsules with an active agent encapsulated in an interior compartment/core inside of a polymer wall. The current invention relates to pH-sensitive microparticles that have a corrosion-detecting or corrosion-inhibiting active agent or active agents dispersed within a polymer matrix of the microparticles. The pH-sensitive microparticles can be used in various coating compositions on metal objects for corrosion detecting and/or inhibiting.

Abstract: Particle in the shape of an encapsulated droplet comprising a core material and a shell material surrounding the core material, the shell material containing maleimide groups, preferably a copolymer of maleimide groups. The shell material contains a copolymer of styrene and maleic anhydride derivatives, of which more than 75 mole %, preferably more than 90 mole % is maleimide, and the average particle size is smaller than 300 nm. The particles are obtained by a process comprising by heating between 80° C. and 195° C., more preferably between 120° C. and 190° C. an ammonium salt of a maleic anhydride containing polymer in the presence of the core material.

Abstract: This invention relates to a method of determining presence, amount and/or activity of a clostridial neurotoxin in a sample, the method comprising or consisting of the following steps: (a) bringing said sample into contact with a liposome, said liposome comprising (aa) at least one receptor on its outer surface, said receptor being capable of binding said neurotoxin and comprising or consisting of (i) a glycolipid and (ii) a peptide or protein; and (ab) a substrate in its interior, said substrate (i) being cleavable by the peptidase comprised in said neurotoxin and (ii) generating a detectable signal upon cleavage, said detectable signal preferably being generated by (1) the donor of a FRET pair, said donor exhibiting increased fluorescence upon cleavage by said peptidase, (2) a luminescent compound formed upon said cleavage, or (3) an enzyme formed upon said cleavage; and (b) determining whether an increase in signal occurs as compared to the absence of said sample, wherein such increase is indicative of the

Abstract: The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise liposomes formed from dimyristoylphosphatidylcholine (“DMPC”); either dimyristoylphosphatidylglycerol (“DMPG”) or dimyristoyltrimethylammonium propane (“DMTAP”) or both DMPC and DMTAP; and at least one sterol; and an antigenic polypeptide comprising a first polypeptide sequence, and a second polypeptide sequence heterologous the first polypeptide sequence which comprises a transmembrane sequence from a membrane protein, said transmembrane sequence having a number of residues sufficient to cross a lipid bilayer, at least nine contiguous residues of which are predicted to form an alpha helix having a hydrophobicity score of about 0.7 or greater.

Abstract: The present invention provides a composition for the treatment of cancer including zwitterionic liposomes consisting essentially of: 50-65 mol % of a phosphatidylcholine lipid, 30-45 mol % of cholesterol, and 2-8 mol % of a PEG-lipid; and cisplatin. Cisplatin is encapsulated in the liposomes in an amount such that the ratio of the total lipid weight to the cisplatin weight is from about 65:1 to about 95:1. Methods for the preparation of liposomal cisplatin and the treatment of cancer are also disclosed.

Abstract: The present invention provides a composition for the treatment of cancer including zwitterionic liposomes consisting essentially of: 50-70 mol % of a phosphatidylcholine lipid, 25-45 mol % of cholesterol, and 2-8 mol % of a PEG-lipid; and oxaliplatin. Oxaliplatin is encapsulated in the liposomes in an amount such that the ratio of the total lipid weight to the oxaliplatin weight is from about 20:1 to about 65:1. Methods for the preparation of liposomal oxaliplatin and the treatment of cancer are also disclosed.

Abstract: The present invention relates to a liposomal formulation containing a therapeutic agent and a process for producing the formulation. The liposomal formulation comprises particular characteristics that enhance uniformity and stability of the formulation. The manufacturing process is a novel process that produces a liposomal formulation of a uniform size with many desirable properties that may be independently controlled. Further, the invention relates to a liposome formulation made in accordance with the manufacturing process.

Abstract: A sustained release microsphere formulation with a high drug load may be formed by a continuous oil-in-water emulsion process by combining an organic dispersed phase with an aqueous continuous phase. The dispersed phase may include an encapsulating polymer, a primary solvent, such as dichloromethane, a pharmaceutically effective amount of an active agent having a solubility relative to the dispersed phase, and a co-solvent, such as benzyl alcohol, which is capable of increasing the solubility of the active agent relative to the dispersed phase. The continuous phase may include an aqueous solution of polyvinyl alcohol and water.

Abstract: The present invention describes processes for the preparation of a lipid blend and a uniform filterable phospholipid suspension containing the lipid blend, such suspension being useful as an ultrasound contrast agent.

Abstract: A method and an apparatus for producing various types of microdroplets. The apparatus has a cross intersection portion at which a first continuous phase, a first dispersion phase, and a second dispersion phase intersect with each other. A first liquid feed device controls the first dispersion phase and a second liquid feed device controls the second dispersion phase. A control device is connected to the first liquid feed device and the second liquid feed device. The first liquid feed device and the second liquid feed device are controlled by a signal from the control device so that microdroplets formed of the first dispersion phase and microdroplets formed of the second dispersion phase are sequentially produced.

Abstract: The essence of the invention is that an aqueous medium is mixed with a lipid component (lipid solution in an organic solvent) by the ejecting introduction (suction) of the lipid component (lipid solution in an organic solvent) into an ejector mixing chamber in the form of a de Laval nozzle by means of the energy from a pressurized jet of the aqueous medium flowing out of the inlet nozzle of the ejector, which jet creates a pressure drop in the convergent part (confuser) of the mixing chamber, wherein an aerosol stream of liposome is formed at the outlet of the divergent part (diffuser) of the mixing chamber.

Abstract: Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.

Abstract: The present invention provides for methods of preparing silk nanoparticles and microparticles, methods of encapsulating an active agent into the silk nano- and microparticles and compositions comprising these silk particles.

Abstract: In a fragrance and/or aroma composition for the targeted release of fragrances and/or aromas in the form of a solid lipid nanoparticle (SLN) dispersion, in which lipid-based nanoparticles are present which are stabilized by an emulsifier monolayer, one or more membrane layers or other auxiliaries, the fragrances and/or aromas are included in the nanoparticles and/or in the emulsifier monolayer or the membrane layers.

Abstract: The present invention provides a method and apparatus for producing polymeric particles with pre-designed size, shape, morphology and composition, and more particularly the present invention uses a microfluidic polymerization reactor for producing same. The present invention disclosed herein provides a process for producing polymer particles with pre-selected shapes. The method includes injecting a first fluid comprising a polymerizable constituent with a controlled flow rate into a microfluidic channel and injecting a second fluid with a controlled flow rate into the microfluidic channel in which the second fluid mixes with the first fluid, the second fluid being immiscible with the first fluid so that the first fluid forms into droplets in the microfluidic channel. The microfluidic channel has pre-selected dimensions to give droplets of pre-selected size, morphology and shape.

Abstract: This invention provides capsules and, more specifically soft capsules, wherein the fill material comprises an emulsified syrup. In particular, the present invention provides a means of encapsulating honey in a gelatin, modified-gelatin or gelatin-free shell material. Furthermore, the capsules described herein are capable of being manufactured using a rotary die apparatus.

Abstract: The present invention describes processes for the preparation of a lipid blend and a uniform filterable phospholipid suspension containing the lipid blend, such suspension being useful as an ultrasound contrast agent.

Abstract: A system that incorporates teachings of the present disclosure may include, for example, a method for applying a force to at least one of an inner stream, an outer stream or both of a combined stream to produce a plurality of capsules, receiving image data, processing the image data, detecting undesirable capsules from the processed image data, applying a bias charge only to the detected undesirable capsules, and segregating the biased undesirable capsules from the unbiased desirable capsules. Additional embodiments are disclosed.

Abstract: Methods of nanoencapsulation are described herein. Embodiments of the method utilize the coacervation of a cationic polyelectrolyte with an anionic polyelectrolyte to form a novel capsular matrix. In particular, the novel methods may be used to encapsulate a suspension of a hydrophobic material such as a carotenoid. The disclosed methods do not require lengthy pH adjustments nor do they require the use of any toxic crosslinking agents. In one embodiment, a method of encapsulation comprises dispersing a hydrophobic compound in an organic solvent to form a solution. The method also comprises admixing an anionic polyelectrolyte and a cationic polyelectrolyte with the suspension to form a mixture. In addition, the method comprises quiescently cooling the mixture so as to cause self-crosslinking of a capsular matrix encapsulating the hydrophobic particles.